Navigation Links
Vycor Medical, Inc. Restatement of Financial Statements
Date:8/15/2011

BOCA RATON, Fla., Aug. 15, 2011 /PRNewswire/ -- Vycor Medical, Inc. ("Vycor" or the "Company") has determined that its historical financial statements for the fiscal quarter ended March 31, 2011, the year ended December 31, 2010, the fiscal quarters ended March 31, 2010, June 30, 2010 and September 30, 2010 and the year ended December 31, 2009 included in the Company's periodic reports filed with the Securities and Exchange Commission ("SEC") require restatement to reflect the proper accounting for certain common stock purchase warrants issued in connection with consulting and other service agreements, and to reflect the proper accounting treatment for the conversion feature associated with certain debt convertible into common stock.

The Company is in the process of preparing amendments to the Forms 10-Q and Forms 10-K for the periods noted above and plans to file amendments to such Forms 10-Q and 10-K with the SEC as soon as possible, incorporating the aforementioned restatements. Further information concerning the restatement is detailed in the Company's Current Report on Form 8-K filed with the SEC on August 15, 2011 relative to this matter. A summary of the matters requiring restatement, which impacts fiscal quarters ended December 31, 2009 to March 2011, is as follows:

1. Warrants issued in connection with consulting or other service agreements have been expensed over the period of the life of the warrant and not the life of the agreement, as required by ASC 505. They have also been recognized on a monthly basis rather than being recorded as a prepaid expense asset at the outset.

2. The Company has, since December 2009, been recognizing and expensing a beneficial conversion discount on convertible debt based on a fair value method; under the intrinsic value method as required under ASC 470, no such discount should have been recognized and expensed.

These matters came to light as a result of a full review of the Company's accounting policies and procedures during the preparation of the Company's financial statements for the periods ended June 30, 2011 and following discussions with the Company's independent registered public accounting firm. The Company's Board of Directors determined to take this action at a meeting on August 12, 2011.

The Company expects that the net impact on the Company's previously reported Net Loss for the 18 month period of October 1, 2009 through March 31, 2011 will be to increase losses by approximately $152,000.

The restatements described above are non-cash items and do not impact Company's operating activities or cash from operations in any way.

About Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (VYCO.BB) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective. Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community. Vycor is ISO 13485:2003 compliant, has FDA 510(K) clearance for brain and spine surgeries, CE Marking and HPB licensing in Canada.

Vycor Medical's subsidiary NovaVision, Inc. researches, develops and provides science-driven light-based neurostimulation therapy and other medical technologies that help restore sight to patients with neurological vision impairments. The company's proprietary, Visual Restoration Therapy (VRT) platform is clinically supported to improve lost vision resulting from stroke, traumatic brain injury ("TBI"), or other acquired brain injury. VRT has FDA 510(K) clearance with patents granted in the US, Canada, and Europe. NovaVision also provides a device that aids in the early identification of visual field deficits: the Head Mounted Perimeter (HMP™) -- a portable and ADA-compliant instrument to aid in the detection and measurement of visual field deficits even in bed-ridden patients.

For the latest information on the company, including media and other coverage, and to learn more, please go online at http://www.vycormedical.com or http://www.novavision.com.

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Media Contact:
Karen Coviello
Kacoviello(at)novavision(dot)com
561-558-2000 ext 218


'/>"/>
SOURCE Vycor Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vycor Medical, Inc. Completes Equity Capital Raise
2. Vycor Medical, Inc. Announces Alvaro Pascual-Leone, MD, PhD as Head of the Strategic Advisory Board of its NovaVision, Inc. Subsidiary
3. Vycor Medical, Inc. Completes Final Close on Equity Capital Raise
4. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
5. Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
6. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
7. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
8. New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
9. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
10. Cardiva Medical, Inc. Announces the Departure of its President and his Appointment as CEO of Innovative Energy, Inc.
11. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... CHAPEL HILL, N.C. , Feb. 5, 2016 /PRNewswire/ ... sector has been slower than other industries to embrace ... that come with utilization. On the medical side, organizations ... to improve everything from clinical trials to adherence. ... recent research from benchmarking firm Best Practices, LLC, Big ...
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: ... Annual Global Healthcare Conference at 9:15 a.m. ET on ... . David W. Meline , executive vice president ... conference. Live audio of the presentation can be accessed from ... Investors. A replay of the webcast will also be available ...
(Date:2/5/2016)...  Redwood Scientific Technologies, Inc. announced today the development ... women balance their hormones. This product will be featuring ... Jason Cardiff , President and CEO. "I am proud ... millions of women across the country and around the ... Our research and development team is confident that through ...
Breaking Medicine Technology:
(Date:2/7/2016)... Michigan (PRWEB) , ... February 07, 2016 , ... ... organ prolapse with the latest techniques and the most minimally invasive approaches. , ... organ prolapse, particularly after menopause. Other risk factors include surgery to the pelvic ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... Plastics, has added Kybella® to his medical and surgical expertise. Technically known as ... FDA injectable medication used as a non-surgical alternative for reduction of fat below ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This conference ... estimated 5000 perioperative nurses in attendance to study the latest evidence-based recommendations ...
Breaking Medicine News(10 mins):